Table 3 Key study end-points
Primary Endpoint | Secondary Endpoints | Exploratory Endpoints |
|---|---|---|
Survival at 6 months | Supplemental O2 requirements | Anti-HEp-2 IFA Titers and Patterns |
Six-minute walk distance | Circulating Immunoglobulin Concentrations | |
AE-IPF Relapses | B Lymphocyte Stimulating Factor | |
Adverse events | Quality of Life (QoL) Measures | |
| Â | Autoantibody repertoires |